MedWatch

FDA approves migraine pill as preventative treatment

Migraine treatment Nurtec, developed by US firm Biohaven, is now approved for preventative and acute use.

Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix

The preventative treatment industry for migraines has gained a new player in the form of US-based firm Biohaven, which can now start competing with companies like Lundbeck, Amgen and Eli Lilly following a recent FDA approval.

The company recently reported that the FDA has approved an application to expand the indication for migraine treatment Nurtec, which was approved eighteen months ago as an acute treatment to be used after the onset of a migraine.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs